CC BY-NC-ND 4.0 · Journal of Social Health and Diabetes 2019; 7(02): 50-53
DOI: 10.1055/s-0039-3401979
Review Article
Novo Nordisk Education Foundation

Diabetes and Insurance

Sujoy Ghosh
1  Department of Endocrinology and Metabolism, I.P.G.M.E&R, West Bengal, India
,
Pradip Mukhopadhyay
1  Department of Endocrinology and Metabolism, I.P.G.M.E&R, West Bengal, India
,
Sarita Bajaj
2  Department of Medicine, Motilal Nehru Medical College, Prayagraj, Uttar Pradesh, India
› Author Affiliations
Further Information

Publication History

Publication Date:
30 March 2020 (online)

  

Abstract

India has healthcare expenditure of more than 5 billion dollars on diabetes-related healthcare management. Globally, approximately 12% of health expenditure is spent on diabetes and related comorbidities. Hospitalization includes hospital and laboratory expenses and cost of medications as the direct cost. India is among the countries, where if the insured dies during the time period specified in the insurance policy and the policy is active, or in force, then a death benefit will be paid. Studies in India reported that medical reimbursement is availed by 21.3% in the high-income group and only 6.4% of the urban low-income group. An average cost of management of diabetic complications like diabetic foot, retinopathy, and patients with two complications was almost close to the average cost of claimed amount. Patients may be advised to take insurance for diabetes when there is any indication of future disease and risk factors contributing to diabetes like a strong family history, obesity, hypertension, and other vascular diseases. Diabetes Safe from Star Health and Varistha Mediclaim from National Insurance were among the first insurance policies to be launched in India.